Opinion|Videos|November 19, 2024
Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry
Author(s)Steven D. Nathan, MD
Key Takeaways
- The study aimed to identify predictors of long-term survival in idiopathic pulmonary fibrosis using the IPF-PRO Registry data.
- A retrospective cohort design was used, analyzing clinical, demographic, and physiological data to develop predictive models.
Steven Nathan, MD, discusses the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry,” which aimed to identify key predictors of long-term survival in IPF using data from the IPF-PRO Registry; the study employed a classification and regression tree model to analyze variables such as FVC percent predicted, oxygen use, BMI, and age, and found that factors such as oxygen use and FVC levels were strong predictors of survival beyond 5 years.
Advertisement
Episodes in this series
- Briefly describe the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From The IPF-PRO Registry.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related to this article
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Oncology leaders discuss where AI delivers value, who bears liability, data readiness, and why humans must stay in the loop for clinical decisions.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5